Company Overview

Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.

  • Name

    Otsuka Holdings Co., Ltd.

  • CEO

    Mr. Tatsuo Higuchi

  • Website

    www.otsuka.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1921

Profile

  • Market Cap

    ¥4,344.69B

  • EV

    ¥4,151.7B

  • Shares Out

    541.46M

  • Revenue

    ¥2,179.96B

  • Employees

    34,388

Margins

  • Gross

    70.66%

  • EBITDA

    20.85%

  • Operating

    16.22%

  • Pre-Tax

    6.7%

  • Net

    5.82%

  • FCF

Returns (5Yr Avg)

  • ROA

    4.87%

  • ROTA

    9.11%

  • ROE

    6.8%

  • ROCE

    8.56%

  • ROIC

    7.15%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    ¥8,450

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    ¥485.89B

  • Net Debt

    -¥237.93B

  • Debt/Equity

    0.09

  • EBIT/Interest

    40.21

Growth (CAGR)

  • Rev 3Yr

    14.66%

  • Rev 5Yr

    10.14%

  • Rev 10Yr

  • Dil EPS 3Yr

    -6.03%

  • Dil EPS 5Yr

    8.18%

  • Dil EPS 10Yr

  • Rev Fwd 2Yr

    5.68%

  • EBITDA Fwd 2Yr

    40.59%

  • EPS Fwd 2Yr

    47.43%

  • EPS LT Growth Est

    26.9%

Dividends

  • Yield

  • Payout

    51.35%

  • DPS

    ¥120

  • DPS Growth 3Yr

    6.27%

  • DPS Growth 5Yr

    3.71%

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

    5.89%

TSE:4578